Focus: Progyny is a fertility benefits and IVF product company focused on women's health, headquartered in New York with a specialized portfolio centered on the Eeva time-lapse imaging system for embryo selection.
Profile data last refreshed 9h ago · AI intelligence enriched 1w ago
Cooling — net -11 jobs in 30d
23 added, 34 removed. Slower than typical.
Progyny offers a focused fertility-tech opportunity with public-market backing, but limited transparency on financials and modest hiring volume warrant careful due diligence before committing.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Progyny
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Progyny's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Progyny Inc stock (US74340E1038): fertility benefits specialist after recent share price swings - AD HOC NEWS
Progyny Inc stock (US74340E1038): fertility benefits specialist after recent share price swings AD HOC NEWS
A Progyny (PGNY) Insider Sold 5,500 Shares for $137,000 - The Motley Fool
A Progyny (PGNY) Insider Sold 5,500 Shares for $137,000 The Motley Fool
Positive Report for Progyny (PGNY) from Goldman Sachs - The Globe and Mail
Positive Report for Progyny (PGNY) from Goldman Sachs The Globe and Mail
Progyny stock (US74340E1038): fertility benefits specialist back in focus after strong quarterly upd - AD HOC NEWS
Progyny stock (US74340E1038): fertility benefits specialist back in focus after strong quarterly upd AD HOC NEWS
Progyny (PGNY) Stock: Trendline Structure Analysis (+2.83%) 2026-04-27 - McClellan Oscillator - The Legal Advocate
Progyny (PGNY) Stock: Trendline Structure Analysis (+2.83%) 2026-04-27 - McClellan Oscillator The Legal Advocate
Progyny (PGNY) Stock: Trendline Structure Analysis (+2.83%) 2026-04-27 - Insider Selling - Newser
Progyny (PGNY) Stock: Trendline Structure Analysis (+2.83%) 2026-04-27 - Insider Selling Newser
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 7 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo